Establishment of an HLA-A*0201 human papillomavirus type 16 tumor model to determine the efficacy of vaccination strategies in HLA-A*0201 transgenic mice

Cancer Research

Volumn 62, Issue 20, 2002, Pages 5792-5799

  Eiben, Gretchen L ^a   Velders, Markwin P ^a   Schreiber, Hans ^b   Cassetti, Maria Cristina ^c   Pullen, Jeffrey K ^c   Smith, Larry R ^c   Kast, W Martin ^a  

^a LOYOLA UNIVERSITY HEALTH SYSTEM   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c WYETH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; DNA VACCINE; EPITOPE; HLA A ANTIGEN; PLASMID DNA; VIRUS RNA; VIRUS VECTOR; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; HLA A*0201 ANTIGEN; HLA-A*0201 ANTIGEN; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; REPRESSOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN PAPILLOMAVIRUS TYPE 16; MOUSE; NONHUMAN; ONCOGENE H RAS; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSGENIC MOUSE; TUMOR MODEL; VACCINATION; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; VIRAL GENE DELIVERY SYSTEM; VIRUS ONCOGENE; WART VIRUS; ANIMAL; C57BL MOUSE; DISEASE MODEL; EXPERIMENTAL NEOPLASM; GENETICS; IMMUNOLOGY;

ANIMALS; CANCER VACCINES; DISEASE MODELS, ANIMAL; ENCEPHALITIS VIRUS, VENEZUELAN EQUINE; EPITOPES; FEMALE; HLA-A ANTIGENS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; ONCOGENE PROTEINS, VIRAL; REPRESSOR PROTEINS; VACCINES, DNA;

EID: 0037107336     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Walboomers, J. M., Jacobs, M. V., Manos, M. M., Bosch, F. X., Kummer, J. A., Shah, K. V., Snijders, P. J., Peto, J., Meijer, C. J., and Munoz, N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol., 189: 12-19, 1999
2. Remmink, A. J., Walboomers, J. M., Helmerhorst, T. J., Voorhorst, F. J., Rozendaal, L., Risse, E. K., Meijer, C. J., and Kenemans, P. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: Natural history up to 36 months. Int. J. Cancer, 61: 306-311, 1995
3. Schiffman, M. H., Bauer, H. M., Hoover, R. N., Glass, A. G., Cadell, D. M., Rush, B. B., Scott, D. R., Sherman, M. E., Kurman, R. J., and Wacholder, S. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J. Natl. Cancer Inst., 85: 958-964, 1993
4. Sun, W., Kuhn, L., Ellerbrock, T., Chiasson, M., Bush, T., and Wright, T. Human papillomavirus infection in women infected with the human immunodeficiency virus. N. Engl. J. Med., 337: 1343-1349, 1997
5. Frisch, M., Biggar, R. J., and Goedert, J. J. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J. Natl. Cancer Inst., 92: 1500-1510, 2000
6. Seedorf, K., Oltersdorf, T., Krammer, G., and Rowekamp, W. Identification of early proteins of the human papilloma viruses type 16 (HPV 16) and type 18 (HPV 18) in cervical carcinoma cells. EMBO J., 6: 139-144, 1987
7. Von Knebel Doeberitz, M., Bauknecht, T., Bartsch, D., and zur Hausen, H. Influence of chromosomal integration on glucocorticoid regulated transcription of growthstimulating papillomavirus E6 E7 genes in cervical carcinoma cells. Proc. Natl. Acad. Sci. USA, 88: 1411-1415, 1991
8. Werness, B. A., Levine, A. J., and Howley, P. M. Association of human papilloma-virus types 16 and 18 E6 proteins with p53. Science (Wash. DC), 248: 76-79, 1990
9. Dyson, N., Howley, P. M., Munger, K., and Harlow, E. The human papillomavirus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product, Science (Wash. DC), 243: 934-940, 1989
10. Ressing, M. E., Sette, A., Brandt, R. M. P., Ruppert, J., Wentworth, P. A., Hartman, M., Oseroff, C., Grey, H. M., Melief, C. J. M., and Kast, W. M. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J. Immunol., 154: 5934-5943, 1995
11. Lin, K. Y., Guarnieri, F. G., Staveley-O'Carroll, K. F., Levitsky, H. I., August, J. T., Pardoll, D. M., and Wu, T. C. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res., 56: 21-26, 1996
12. Velders, M. P., McElhiney, S., Cassetti, M. C., Eiben, G. L., Higgins, T., Kovacs, G. R., Elmishad, A. G., Kast, W. M., and Smith, L. R. Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA. Cancer Res., 61: 7861-7867, 2001
13. Feltkamp, M. C. W., Smits, H. L., Vierboom, M. P. M., Minnaar, R. P., de Jongh, M., Drijthout, J. W., ter Schegget, J., Melief, C. J. M., and Kast, W. M. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-tansformed cells. Eur. J. Immunol., 23: 2242-2244, 1993
14. Fernando, G. J., Murray, B., Zhou, J., and Frazer, I. H. Expression, purification and immunological characterization of the transforming protein E7, from cervical cancer-associated human papillomavirus type 16. Clin. Exp. Immunol., 115: 397-403, 1999
15. Debruijn, M. L. H., Schuurhuis, D. H., Vierboom, M. P. M., Vermeulen, H., Decock, K. A. J., Ooms, M. E., Ressing, M. E., Toebes, M., Franken, K. L. M. C., Drijfhout, J. W., Ottenhoff, T. H. M., Offringa, R., and Melief, C. J. M. Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class 1-restricted protection to HPV16-induced tumor cells. Cancer Res., 58: 724-731, 1998
16. Shi, W., Bu, P., Liu, J., Polack, A., Fisher, S., and Qiao, L. Human papillomavirus type 16 E7 DNA vaccine: Mutation in the open reading frame of E7 enhances specific cytotoxic T-lymphocyte induction and antitumor activity. J. Virol., 73: 7877-7881, 1999
17. Greenstone, H. L., Nieland, J. D., de Visser, K. E., De Bruijn, M. L., Kirnbauer, R., Roden, R. B. S., Lowy, D. R., Kast, W. M., and Schiller, J. T. Chimeric papilloma-virus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc. Natl. Acad. Sci. USA, 95: 1800-1805, 1998
18. Peng, S., Frazer, I. H., Fernando, G. J., and Zhou, J. Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway. Virology, 240: 147-157, 1998
19. Schafer, K., Muller, M., Faath, S., Henn, A., Osen, W., Zentgraf, H, Benner, A., Gissmann, L., and Jochmus, I. Immune response to human papillomavirus 16 LIE7 chimeric virus-like particles: Induction of cytotoxic T cells and specific tumor protection. Int. J. Cancer, 81: 881-888, 1999
20. Ji, H., Wang, T. L., Chen, C. H., Pai, S. I., Hung, C. F., Lin, K. Y., Kurman, R. J., Pardoll, D. M., and Wu, T. C. Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors. Hum. Gene Ther., 10: 2727-2740, 1999
21. Velders, M. P., Weijzen, S., Eiben, G. L., Elmishad, A. G., Kloetzel, P. M., Higgins, T., Ciccarelli, R. B., Evans, M., Man, S., Smith, L., and Kast, W. M. Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine. J. Immunol. 166: 5366-5373, 2001
22. Toes, R. E. M., Offringa, R., Blom, R. J. J., Melief, C. J. M., and Kast, W. M. Peptide vaccination can lead to enhance tumor growth through specific T-cell tolerance induction. Proc. Natl. Acad. Sci. USA, 93: 7855-7860, 1996
23. Da Silva, D. M., Eiben, G. L., Fausch, S. C., Wakabayashi, M. T., Rudolf, M. P., Velders, M. P., and Kast, W. M. Cervical cancer vaccines: Emerging concepts and developments. J. Cell Physiol., 186: 169-182, 2001
24. MacDonald, G. H., and Johnston, R. E. Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis. J. Virol., 74: 914-922, 2000
25. Engelhard, V. H., Lacy, E., and Ridge, J. P. Influenza A-specific HLA-A2.1-restricted cytotoxic T lymphocytes from HLA-A2.1 transgenic mice recognize fragments of the M1 protein. J. Immunol., 146: 1226-1232, 1991
26. Shirai, M., Arichi, T., Nishioka, M., Nomura, T., Ikeda, K., Kawanishi, K., Engelhard, V. H., Feinstone, S. M., and Berzofsky, J. A. CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1. J. Immunol., 154: 2733-2742, 1995
27. Kast, W. M., Brandt, R. M. P., Sidney, J., Drijfhout, J. W., Kubo, R. T., Grey, H. M., Melief, C. J. M., and Sette, A. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J. Immunol., 152: 3904-3912, 1994
28. Correale, P., Walmsley, K., Nieroda, C., Zaremba, S., Zhu, M., Schlom, J., and Tsang, K. Y. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J. Natl. Cancer Inst., 89: 293-300, 1997
29. Crish, J. F., Bone, F., Balasubramanian, S., Zaim, T. M., Wagner, T., Yun, J., Rorke, E. A., and Eckert, R. L. Suprabasal expression of the human papillomavirus type 16 oncoproteins in mouse epidermis alters expression of cell cycle regulatory proteins. Carcinogenesis (Lond.), 21: 1031-1037, 2000
30. Durst, M., Glitz, D., Schneider, A., and zur Hausen, H. Human papillomavirus type 16 (HPV 16) gene expression and DNA replication in cervical neoplasia: Analysis by in situ hybridization. Virology, 189: 132-140, 1992
31. Ressing, M. E., van Driel, W. J., Celis, E., Sette, A., Brandt, R. M. P., Hartman, M., Anholts, J. D. H., Schreuder, G. M. T., Bram ter Harmsel, W., Fleuren, G. J., Trimbos, B. J., Kast, W. M., and Melief, C. J. M. Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A*0201-restricted E7-encoded epitope. Cancer Res., 56: 582-588, 1996
32. Evans, E. M., Man, S., Evans, A. S., and Borysiewicz, L. K. Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes. Cancer Res., 57: 2943-2950, 1997
33. Bullock, T. N., Colella, T. A., and Engelhard, V. H. The density of peptides displayed by dendritic cells affects immune responses to human tyrosinase and gp100 in HLA-A2 transgenic mice. J. Immunol., 164: 2354-2361, 2000
34. Irwin, M. J., Heath, W. R., and Sherman, L. A. Species-restricted interactions between CD8 and the α3 domain of class I influence the magnitude of the xenogeneic response. J. Exp. Med., 170: 1091-1101, 1989
35. Samberg, N. L., Scarlett, E. C., and Stauss, H. J. The alpha 3 domain of major histocompatibility complex class I molecules plays a critical role in cytotoxic T lymphocyte stimulation. Eur. J. Immunol., 19: 2349-2354, 1989
36. Kalinke, U., Arnold, B., and Hammerling, G. J. Strong xenogeneic HLA response in transgenic mice after introducing an α3 domain into HLA B27. Nature (Lond.), 348: 642-644, 1990
37. Vitiello, A., Marchesini, D., Furze, J., Sherman, L. A., and Chesnut, R. W. Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J. Exp. Med., 173: 1007-1015, 1991
38. van Driel, W. J., Ressing, M. E., Kenter, G. G., Brandt, R. M., Krul, E. J., van Rossum, A. B, Schuuring, E., Offringa, R., Bauknecht, T., Tamm-Hermelink, A., van Dam, P. A., Fleuren, G. J., Kast, W. M., Melief, C. J., and Trimbos, J. B. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: Clinical evaluation of a Phase I-II trial. Eur. J. Cancer, 35: 946-952, 1999
39. Ressing, M. E., van Driel, W. J., Brandt, R. M. P., Kenter, G. G., de Jong, J. H., Bauknecht, T., Fleuren, G. J., Hoogerhout P., Offringa, R., Sette, A., Cells, E., Grey H., Tdmbos, B. J., Kast, W. M., and Melief, C. J. M. Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J. Immunother., 23: 255-266, 2000
40. Muderspach, L., Wilczyneki, S., Roman, L., Bade, L., Felix, J., Small, L. A., Kast, W. M., Fascia, G., Marty, V., and Weber, J. A Phase I trial of a HPV peptide vaccine for women with high grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin. Cancer Res., 6: 3406-3416, 2000